TRINETRA › Sectors › Healthcare
Orchid Pharma Limited (ORCHPHARMA) — share price, P/E and fundamentals
Orchid Pharma Limited (NSE: ORCHPHARMA) closed at ₹836.45 on 30 Oct 2026, +15.4% over one year, against a 52-week range of ₹480.00 – ₹1,143.50.
In the quarter ended 30 Jun 2026 (consolidated, filed 14 Aug 2026) it reported revenue of ₹304 cr and net profit of ₹3 cr, a 1.1% net margin; revenue grew 75.9% and profit fell 80.7% year on year.
On four consecutive filed quarters its trailing P/E is 467.0; since 28 May 2025 its own P/E has ranged from 32.0 to 900.2 (median 44.2), and today's reading is higher than 87% of those 352 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 0.8%, ROCE 1.1%, debt-to-equity 0.19, Piotroski F-score 4 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 5% of 64 sector peers; PBT margin higher than 3% of 64 sector peers; ROE higher than 6% of 64 sector peers.
Key figures
| Last close | ₹836.45 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -23.7% / +47.6% / +15.4% |
| 52-week low – high | ₹480.00 – ₹1,143.50 |
| Market capitalisation | ₹5,009 cr |
| Trailing P/E | 467.0 |
| Price / book | 3.20 |
| EV / EBITDA | 84.3 |
| Earnings yield | 0.2% |
| TTM EPS | ₹1.79 |
| TTM net profit | ₹11 cr |
| Quarter revenue | ₹304 cr |
| Quarter net profit | ₹3 cr |
| Net margin | 1.1% |
| Revenue growth (YoY) | +75.9% |
| Profit growth (YoY) | -80.7% |
| Return on equity | 0.8% |
| ROCE | 1.1% |
| Debt / equity | 0.19 |
| Current ratio | 1.89 |
| Free cash flow | ₹-264 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹6.8 cr |
Against Healthcare peers
| Metric | ORCHPHARMA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 1.06 | 12.89 | 5 |
| PBT margin | 0.87 | 17.68 | 3 |
| ROE | 0.82 | 13.87 | 6 |
| ROCE | 1.10 | 17.26 | 5 |
| Debt / equity | 0.19 | 0.11 | 60 |
| Cash conversion | 12.62 | 1.25 | 98 |
| Trailing P/E | 466.97 | 43.26 | 100 |
| P/B | 3.20 | 6.02 | 15 |
Questions
What is the P/E ratio of Orchid Pharma Limited?
Orchid Pharma Limited's trailing P/E is 467.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 28 May 2025 its P/E has ranged 32.0–900.2.
What were Orchid Pharma Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Orchid Pharma Limited reported revenue of ₹304 cr and net profit of ₹3 cr (consolidated), filed with the exchange on 14 Aug 2026.
What is Orchid Pharma Limited's ROE?
Return on equity is 0.8% based on the balance sheet dated 31 Mar 2026.
Does Orchid Pharma Limited have debt?
Debt-to-equity is 0.19 on the balance sheet dated 31 Mar 2026.
What is ORCHPHARMA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ORCHPHARMA traded between ₹480.00 and ₹1,143.50.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.